@entity1033 kinetics in XXXX .

@entity1033 @entity1 @entity3073 @entity177 @entity454
@entity1033 ( @entity3073 ) is almost entirely eliminated by the kidneys and has a terminal plasma half-life (t1/2) of 2 to 3 hr in subjects with normal renal function. To determine the drug's kinetics and tolerance in @entity1 with severe @entity177 , six anuric subjects on long-term hemodialysis were studied. Each received a 1-hr infusion of 2.5 mg/kg IV @entity3073 . The kinetics are well described by a two-compartment open model. @entity3073 terminal plasma t 1/2 and the total body clearance were 19.5 +/- 5.9 hr (mean +/- SD) and 28.6 +/- 9.5 ml/min/1.73 m2. Peak (end of infusion) and 8- and 24-hr plasma @entity3073 concentrations were 37.5 +/- 23.3, 10.3 +/- 2.9, and 6.4 +/- 2.4 microM. Approximately 48 hr after the start of the infusion the subjects were hemodialyzed for 6 hr. The pre- and posthemodialysis @entity3073 plasma levels were 2.74 +/- 1.38 and 1.11 +/- 0.60 microM. The terminal @entity3073 t1/2 during hemodialysis was 5.7 +/- 0.85 hr. During hemodialysis paired arterial and venous samples showed that @entity3073 was readily dialyzed, with a mean coefficient of extraction of 0.45 +/- 0.12. The dialysis clearance of @entity1033 was 81.8 +/- 12.6 ml/min. None of the @entity1 had any @entity3073 -related adverse effects. Since @entity3073 elimination is markedly reduced in @entity454 and because @entity3073 is readily hemodialyzible, dosage modification are needed to avoid cumulation and to replace dialyzed drug.
